With Carboxylic Acid, Ester Or Metal Salt Thereof Patents (Class 514/163)
  • Patent number: 8580770
    Abstract: A method for treating actinic keratosis or basal cell carcinoma. A person's skin is inspected to identify areas that exhibit lesions indicating actinic keratosis or basel cell carcinoma. If such areas are found, a treating composition is applied to the skin in that area. The treating composition may include avobenzone, octocrylene, octyl salicylate, and oxybenzone, and optionally may additionally include SD alcohol 40, C12-15 alkyl benzoate, acrylates, octylacrylamide copolymer, hydroxypropyl cellulose, PEG-40 sorbitan peroleate, tocopherol, and aloe barbadensis extract. The skin is monitored regularly to determine whether the skin lesions remain, and the treating composition is applied several times daily for a period of at least two months until the area is substantially free of the lesions.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: November 12, 2013
    Inventor: Bryan Burney
  • Publication number: 20130295169
    Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventor: Biogen Idec MA Inc.
  • Publication number: 20130289006
    Abstract: Compositions are disclosed that contain an effective hyperpigmentation-treating active agent and a pharmaceutically-acceptable carrier or vehicle. Methods of using the compositions to treat hyperpigmentation are also disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 31, 2013
    Inventor: Bryan B. Fuller
  • Patent number: 8569320
    Abstract: The invention relates to a topical gel composition for use in the treatment of actinic keratosis comprising (a) an active agent for treatment of actinic keratosis, (b) a keratolytically active agent, (c) a gel former, and (d) an organic solvent.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: October 29, 2013
    Assignee: Almirall Hermal GmbH
    Inventors: Manfred Melzer, Carmen Matthies, Klaus Treudler, Christoph Willers, Henning Mallwitz
  • Patent number: 8568759
    Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 29, 2013
    Assignee: W. Neudorff GmbH KG
    Inventor: Diana L. Parker
  • Publication number: 20130280323
    Abstract: Disclosed herein is a soft elastic capsule that includes an acid resistant, capsule shell that defines an encapsulated space having a predetermined volume, a liquid or semisolid fill comprising a first active ingredient located within the encapsulated space, and a first compressed tablet a having a minimal dimension of 2 mm, being located within the encapsulated space, unanchored to the capsule shell, and surrounded by the fill, said tablet comprising a second active ingredient that is substantially insoluble in the fill. A method of manufacturing a soft elastic capsule is also disclosed.
    Type: Application
    Filed: April 12, 2013
    Publication date: October 24, 2013
    Inventors: Qi Fang, Don A. Archibald, Madhu Sudan Hariharan, Roger E. Gordon
  • Publication number: 20130281411
    Abstract: Compositions are disclosed that contain an effective inflammatory-dermatological disease-treating or condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle. Methods of using the compositions to treat a subject's skin are also disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 24, 2013
    Inventor: Bryan B. Fuller
  • Publication number: 20130273172
    Abstract: The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 17, 2013
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Publication number: 20130261092
    Abstract: The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the disease or disorder. In exemplary embodiments, a combination of abscisic acid and a thiazolidinedione (TZD) is provided for increased insulin sensitivity and improved (i.e., reduced) obesity-induced inflammation.
    Type: Application
    Filed: May 30, 2013
    Publication date: October 3, 2013
    Inventors: Josep BASSAGANYA-RIERA, Amir J. GURI, Raquel HONTECILLAS
  • Publication number: 20130237505
    Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 12, 2013
    Applicant: CONCERT, LLC
    Inventor: William Paul Purcell
  • Publication number: 20130216615
    Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.
    Type: Application
    Filed: February 6, 2013
    Publication date: August 22, 2013
    Inventor: David Goldman
  • Publication number: 20130210776
    Abstract: The invention relates to a composition for the treatment of superficial lesions, in particular skin lesions, mucous membrane lesions and/or nail lesions, an applicator comprising such a composition and the use of such a composition. The composition comprises an effective amount of trichloroacetic acid, at least one thickener, and at a physiologically acceptable solvent. And is effective against a plethora of superficial lesions selected from the group consisting of viral warts, verrucae, water warts (molluscum contagiosum), corns and calluses, and skin hyperpigmentation: age spots, solar lentigo, senial lentigo, acne, keratosis pilaris, actinic keratosis, mouth ulcers (canker sores), cold sores, ingrown toenails, onychomycosis, eyelid xanthelasma.
    Type: Application
    Filed: July 15, 2011
    Publication date: August 15, 2013
    Applicant: Progressare Medinvest B.V.
    Inventors: Maikel Hendriks, Pieternella Bouter, Katarzyna Kolodziej
  • Publication number: 20130210777
    Abstract: The present invention is directed to compositions and processes for their use that ameliorate the appearance of bruises, making them less cosmetically unappealing. The composition functions by acting both as a humectant and occlusive agent attracting water, returning the skin surface to a smooth state and holding water in place. The re-establishment of a homeostatic state in the skin results in a rapid dissipation of the negative cosmetic effects of the bruise on the skin.
    Type: Application
    Filed: February 25, 2013
    Publication date: August 15, 2013
    Inventors: Bruce A. Cranner, Anne-Marie T. Karp, C. Scott Danos
  • Publication number: 20130202704
    Abstract: The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the synthesis of mexiprostil.
    Type: Application
    Filed: October 18, 2011
    Publication date: August 8, 2013
    Applicant: COSMO TECHNOLOGIES LTD.
    Inventors: Alessandro Assandri, Luigi Moro
  • Patent number: 8497257
    Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: July 30, 2013
    Assignee: Amderma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sanchez
  • Patent number: 8492366
    Abstract: The solubility in solvent media, notably alcoholic media, of the beta-hydroxy acids (“BHAs”), notably the chemical skin peeling agent salicylic acid, is markedly enhanced by solubilizing same in the presence of at least one alpha-hydroxy acid (“AHA”); higher potency, more concentrated BHA skin peel products are thus formulated.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: July 23, 2013
    Assignee: Societe L'Oreal S.A.
    Inventors: Marc Cornell, Hani Fares, Sidney Peter Foltis, Isabelle Hansenne
  • Patent number: 8492367
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: July 23, 2013
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20130142882
    Abstract: The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds.
    Type: Application
    Filed: November 14, 2012
    Publication date: June 6, 2013
    Applicant: GOLDEN BIOTECHNOLOGY CORPORATION
    Inventor: GOLDEN BIOTECHNOLOGY CORPORATION
  • Patent number: 8445015
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: May 21, 2013
    Assignee: Wellesley Pharmaceuticals, LLC
    Inventor: David A. Dill
  • Publication number: 20130071450
    Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 21, 2013
    Applicant: COVIDIEN LP
    Inventor: Covidien LP
  • Publication number: 20130039869
    Abstract: Regimen for the treatment of rosacea include the application of an anti-redness composition to at least a portion of the cleansed area of skin afflicted with rosacea. The regimen may include the application of one or more of a polymetal complex, a composition containing metronidazole, and/or a protective composition. Kits containing components useful in performing such regimens are also described.
    Type: Application
    Filed: February 8, 2012
    Publication date: February 14, 2013
    Applicant: JR CHEM, LLC
    Inventors: Jose E. Ramirez, Hovig Ounanian
  • Patent number: 8357129
    Abstract: Skin rejuvenation system and method in which a pure plant collagen carrier is saturated with a solution of collagen, allantoin, amino acid, propanediol, glycerin, algae, plant DNA living cells, epidermal growth factor, Vitamin E, hyaluronic acid, rose essential, water, and peptide, and the saturated carrier is applied to the skin to be rejuvenated.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: January 22, 2013
    Assignee: Physicans Products, Inc.
    Inventors: Janet R. Graham, Douglas A. Ginter
  • Publication number: 20120322024
    Abstract: Provided herein is a strip, shaped for the application to the labile surface of the front teeth and/or gums of a subject, which strip is provided with at least one oral care composition for delivery to a pre-determined area of the teeth and/or gums of the subject. Also provided herein are uses for delivery of compositions. Further provided are uses of the strip in combination with a dental device.
    Type: Application
    Filed: June 20, 2012
    Publication date: December 20, 2012
    Inventors: Guy De Vreese, Robin List
  • Publication number: 20120316140
    Abstract: A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia.
    Type: Application
    Filed: June 13, 2011
    Publication date: December 13, 2012
    Applicant: PHARMSTAR PHARMACEUTICALS, INC.
    Inventor: Howard Phykitt
  • Publication number: 20120302529
    Abstract: A method for treating actinic keratosis or basal cell carcinoma. A person's skin is inspected to identify areas that exhibit lesions indicating actinic keratosis or basel cell carcinoma. If such areas are found, a treating composition is applied to the skin in that area. The treating composition may include avobenzone, octocrylene, octyl salicylate, and oxybenzone, and optionally may additionally include SD alcohol 40, C12-15 alkyl benzoate, acrylates, octylacrylamide copolymer, hydroxypropyl cellulose, PEG-40 sorbitan peroleate, tocopherol, and aloe barbadensis extract. The skin is monitored regularly to determine whether the skin lesions remain, and the treating composition is applied several times daily for a period of at least two months until the area is substantially free of the lesions.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 29, 2012
    Inventor: Bryan Burney
  • Publication number: 20120301549
    Abstract: Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.
    Type: Application
    Filed: January 26, 2011
    Publication date: November 29, 2012
    Applicant: HANMI SCIENCE CO., LTD.
    Inventors: Jong Soo Woo, Jae Hyun Park, Yong Il Kim, Young Jun Na, Jun Young Choi, Yun Ah Lee
  • Publication number: 20120294943
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Application
    Filed: July 27, 2012
    Publication date: November 22, 2012
    Applicant: Wellesley Pharmaceuticals, LLC
    Inventor: David A. DILL
  • Publication number: 20120276206
    Abstract: The invention relates to an improved method of manufacturing substantially spherical/ball-shaped tartaric acid starter pellets which are suitable for preparing active substance-containing medicament formulations, as well as the pellets as such that may be obtained in this way, and their use as starting material for the preparation of active substance-containing medicament formulations.
    Type: Application
    Filed: March 24, 2009
    Publication date: November 1, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Johann-Georg Maier
  • Patent number: 8287904
    Abstract: A stable soft gel dosage form for acetylsalicylic acid (ASA), aspirin, is provided wherein soft gel capsules containing the ASA can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over the period of six months. A suspension of ASA in a monoglyceride component comprising more than about 50% glyceryl monooleate is packaged in a soft gelatin capsule, which can be substantially free of other components. The ASA in this composition is resistant to hydrolysis from water contained within the soft gelatin matrix or diffusing through the matrix. Methods of preparation and methods of use are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: October 16, 2012
    Inventor: Lionel Borkan
  • Publication number: 20120244221
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Publication number: 20120202778
    Abstract: The present invention relates to the use of at least one fatty acid of the omega-3 group, selected from among ?-linolenic acid and stearidonic acid, and of at least one polyphenol as an agent for increasing the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid, for preparing a food, health, or pharmaceutical composition to be administered to a human being or to an animal.
    Type: Application
    Filed: July 15, 2010
    Publication date: August 9, 2012
    Inventors: Michel De Lorgeril, Patricia Salen
  • Publication number: 20120189684
    Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract.
    Type: Application
    Filed: July 19, 2010
    Publication date: July 26, 2012
    Applicant: Reckitt Benckiser Healthcare International Limited
    Inventors: Carolyn Buckley, Stuart Jackson, Neil Kilcullen, Diane Marie Pavis
  • Publication number: 20120184513
    Abstract: The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 19, 2012
    Applicant: Givaudan SA
    Inventors: Andreas NATSCH, Michael WASESCHA
  • Patent number: 8211876
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: July 3, 2012
    Assignee: The Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20120164192
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.
    Type: Application
    Filed: March 19, 2012
    Publication date: June 28, 2012
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Publication number: 20120164193
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Application
    Filed: March 19, 2012
    Publication date: June 28, 2012
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 8206691
    Abstract: A cosmetic composition is provided including a water-insoluble UV-A sunscreen agent having a ?max at 330-380 nm, a water-insoluble UV-B sunscreen agent having a ?max between 280 and 320 nm, and a water-soluble sunscreen agent having a ?max between 280 and 400 nm, in combination with a photo protective enhancing agent which is a stearyl alkanolamide of structure R1C(O)NR2—R3OH wherein R1 is a C17 radical, R2 is hydrogen or a C1-C6 radical, and R3 is a C2-C8 radical, in a cosmetically acceptable carrier.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: June 26, 2012
    Assignee: Conopco, Inc.
    Inventors: Jack Polonka, Luis Roberto Misso
  • Publication number: 20120141554
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.
    Type: Application
    Filed: January 4, 2012
    Publication date: June 7, 2012
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Publication number: 20120135050
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Application
    Filed: January 4, 2012
    Publication date: May 31, 2012
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. DILL
  • Publication number: 20120087947
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Application
    Filed: August 15, 2011
    Publication date: April 12, 2012
    Applicant: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20120088742
    Abstract: Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.
    Type: Application
    Filed: June 21, 2010
    Publication date: April 12, 2012
    Applicant: Tetra, Sia
    Inventors: Ivars Kalvins, Anatolijs Birmans, Maris Veveris, Antons Lebedevs, Anatolijs Misnovs
  • Publication number: 20120082634
    Abstract: The present invention relates to compounds, and compositions, useful for treating dyslipidemia.
    Type: Application
    Filed: July 1, 2011
    Publication date: April 5, 2012
    Inventors: Mark Ledwidge, Pat O'Flynn, John Gilmer
  • Publication number: 20120052118
    Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channelguides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.
    Type: Application
    Filed: July 18, 2011
    Publication date: March 1, 2012
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
  • Patent number: 8124583
    Abstract: The present invention is directed to a composition useful for making homogeneously mineralized self assembled peptide-amphiphile nanofibers and nanofiber gels. The composition is generally a solution comprised of a positively or negatively charged peptide-amphiphile and a like signed ion from the mineral. Mixing this solution with a second solution containing a dissolved counter-ion of the mineral and/or a second oppositely charged peptide amphiphile, results in the rapid self assembly of the peptide-amphiphiles into a nanofiber gel and templated mineralization of the ions. Templated mineralization of the initially dissolved mineral cations and anions in the mixture occurs with preferential orientation of the mineral crystals along the fiber surfaces within the nanofiber gel. One advantage of the present invention is that it results in homogenous growth of the mineral throughout the nanofiber gel.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: February 28, 2012
    Assignee: Northwestern University
    Inventors: Samuel I. Stupp, Elia Beniash, Jeffrey D. Hartgerink
  • Publication number: 20120046251
    Abstract: The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to reduce or prevent niacin-induced cutaneous vasodilation (“flushing”) in subjects suffering from this undesirable side effect of receiving therapeutic amounts of niacin.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 23, 2012
    Applicant: The Regents of the University of California
    Inventors: Saul Schaefer, Bruce D. Hammock, Ahmet Bora Inceoglu
  • Publication number: 20120045507
    Abstract: A stable soft gel dosage form for acetylsalicylic acid (ASA), aspirin, is provided wherein soft gel capsules containing the ASA can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over the period of six months. A suspension of ASA in a monoglyceride component comprising more than about 50% glyceryl monooleate is packaged in a soft gelatin capsule, which can be substantially free of other components. The ASA in this composition is resistant to hydrolysis from water contained within the soft gelatin matrix or diffusing through the matrix. Methods of preparation and methods of use are also provided.
    Type: Application
    Filed: August 19, 2010
    Publication date: February 23, 2012
    Inventor: Lionel Borkan
  • Patent number: 8119618
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: February 21, 2012
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20120022001
    Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.
    Type: Application
    Filed: September 12, 2011
    Publication date: January 26, 2012
    Applicant: STABLE SOLUTIONS LLC
    Inventor: David F. Driscoll
  • Publication number: 20120015032
    Abstract: The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients.
    Type: Application
    Filed: August 8, 2008
    Publication date: January 19, 2012
    Applicant: HANALL PHARMACEUTICAL COMPANY, LTD.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Sang Ouk Sun
  • Publication number: 20120015912
    Abstract: The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.
    Type: Application
    Filed: January 7, 2011
    Publication date: January 19, 2012
    Applicant: Action Medicines
    Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Maria Luisa Krauel, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez